The role of inflammatory cytokines in diabetic nephropathy.

Cytokines act as pleiotropic polypeptides regulating inflammatory and immune responses through actions on cells. They provide important signals in the pathophysiology of a range of diseases, including diabetes mellitus. Chronic low-grade inflammation and activation of the innate immune system are closely involved in the pathogenesis of diabetes and its microvascular complications. Inflammatory cytokines, mainly IL-1, IL-6, and IL-18, as well as TNF-alpha, are involved in the development and progression of diabetic nephropathy. In this context, cytokine genetics is of special interest to combinatorial polymorphisms among cytokine genes, their functional variations, and general susceptibility to diabetic nephropathy. Finally, the recognition of these molecules as significant pathogenic mediators in diabetic nephropathy leaves open the possibility of new potential therapeutic targets.

[1]  M. Cooper,et al.  Agents in development for the treatment of diabetic nephropathy , 2008, Expert opinion on emerging drugs.

[2]  小池 伸彦 Induction of reactive oxygen species from isolated rat glomeruli by protein kinase C activation and TNF-α stimulation, and effects of a phosphodiesterase inhibitor , 2008 .

[3]  Craig S. Wong,et al.  Cytokine gene polymorphism and progression of renal and cardiovascular diseases. , 2007, Kidney international.

[4]  Y. Moriwaki,et al.  Effect of TNF-α inhibition on urinary albumin excretion in experimental diabetic rats , 2007, Acta Diabetologica.

[5]  J. Nadler,et al.  Inflammatory mechanisms of diabetic complications , 2007, Current diabetes reports.

[6]  G. Ramesh,et al.  Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. , 2007, Kidney international.

[7]  T. Nakagawa Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. , 2007, American journal of physiology. Renal physiology.

[8]  J. Chan,et al.  Aberrant activation profile of cytokines and mitogen‐activated protein kinases in type 2 diabetic patients with nephropathy , 2007, Clinical and experimental immunology.

[9]  S. Kaneko,et al.  Induction of reactive oxygen species from isolated rat glomeruli by protein kinase C activation and TNF-alpha stimulation, and effects of a phosphodiesterase inhibitor. , 2007, Life sciences.

[10]  K. Nath,et al.  Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. , 2007, Kidney international.

[11]  T. Coffman,et al.  Toward a mouse model of diabetic nephropathy: is endothelial nitric oxide synthase the missing link? , 2007, Journal of the American Society of Nephrology : JASN.

[12]  R. Komers,et al.  CYCLO‐OXYGENASE‐2 INHIBITION ATTENUATES THE PROGRESSION OF NEPHROPATHY IN UNINEPHRECTOMIZED DIABETIC RATS , 2007, Clinical and experimental pharmacology & physiology.

[13]  Y. Moriwaki,et al.  Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. , 2007, Acta diabetologica.

[14]  P. Dandona,et al.  Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade , 2007, Journal of Human Hypertension.

[15]  J. Navarro,et al.  Renal Pro-Inflammatory Cytokine Gene Expression in Diabetic Nephropathy: Effect of Angiotensin-Converting Enzyme Inhibition and Pentoxifylline Administration , 2007, American Journal of Nephrology.

[16]  J. Navarro,et al.  Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  J. Navarro,et al.  Inflammation and diabetic nephropathy , 2006, Current diabetes reports.

[18]  S. Kadayıfçılar,et al.  Elevated intravitreal interleukin-6 levels in patients with proliferative diabetic retinopathy. , 2006, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[19]  S. Sizmaz,et al.  Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy , 2006, Eye.

[20]  Jaipaul Singh,et al.  Inflammatory Process in Type 2 Diabetes , 2006 .

[21]  Felix Eichinger,et al.  Modular Activation of Nuclear Factor-κB Transcriptional Programs in Human Diabetic Nephropathy , 2006, Diabetes.

[22]  A. Goldfine,et al.  Inflammation and insulin resistance. , 2006, The Journal of clinical investigation.

[23]  M. Rodríguez-Moran,et al.  Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial. , 2006, Clinical nephrology.

[24]  Y. Aso,et al.  Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. , 2006, The Journal of clinical endocrinology and metabolism.

[25]  D. Levine Hyperfiltration, nitric oxide, and diabetic nephropathy , 2006, Current hypertension reports.

[26]  D. Cha,et al.  Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. , 2006, Journal of the American Society of Nephrology : JASN.

[27]  M. Hollegaard,et al.  Cytokine gene polymorphism in human disease: on-line databases, Supplement 3 , 2006, Genes and Immunity.

[28]  T. Pantsulaia Role of TGF-beta in pathogenesis of diabetic nephropathy. , 2006, Georgian medical news.

[29]  S. Rich Genetics of diabetes and its complications. , 2006, Journal of the American Society of Nephrology : JASN.

[30]  Jaipaul Singh,et al.  Inflammatory process in type 2 diabetes: The role of cytokines. , 2006, Annals of the New York Academy of Sciences.

[31]  R. Atkins,et al.  Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. , 2006, Kidney international.

[32]  K. Ley,et al.  Leukocyte recruitment and vascular injury in diabetic nephropathy. , 2006, Journal of the American Society of Nephrology : JASN.

[33]  W. Jeffcoate,et al.  The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes , 2005, The Lancet.

[34]  C. Flores,et al.  Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. , 2005, Kidney international. Supplement.

[35]  H. Makino,et al.  Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. , 2005, Diabetes care.

[36]  J. Navarro,et al.  Role of inflammation in diabetic complications. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[37]  N. Perico,et al.  Emerging drugs for diabetic nephropathy , 2005, Expert opinion on emerging drugs.

[38]  T. Lee,et al.  Genetics of diabetic nephropathy in type 2 DM: candidate gene analysis for the pathogenic role of inflammation , 2005, Nephrology.

[39]  F. Jamali,et al.  Protective Effects of Angiotensin II Interruption: Evidence for Antiinflammatory Actions , 2005, Pharmacotherapy.

[40]  M. Rodríguez-Moran,et al.  Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients--a randomized, equivalent trial. , 2005, Clinical nephrology.

[41]  J. Navarro,et al.  Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. , 2005, Journal of the American Society of Nephrology : JASN.

[42]  K. Tuttle Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. , 2005, Journal of the American Society of Nephrology : JASN.

[43]  R. Atkins,et al.  Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. , 2005, Journal of the American Society of Nephrology : JASN.

[44]  Mark E. Williams,et al.  The next generation of diabetic nephropathy therapies: an update. , 2005, Advances in chronic kidney disease.

[45]  A. Krolewski,et al.  Evidence for different susceptibility genes for proteinuria and ESRD in type 2 diabetes. , 2005, Advances in chronic kidney disease.

[46]  M. Mussap,et al.  Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. , 2005, Journal of the American Society of Nephrology : JASN.

[47]  L. Gesualdo,et al.  Pathogenetic mechanisms of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.

[48]  M. Cooper,et al.  Agents in development for the treatment of diabetic nephropathy , 2005, Expert opinion on investigational drugs.

[49]  W. Chu,et al.  Molecular screening and association analyses of the interleukin 6 receptor gene variants with type 2 diabetes, diabetic nephropathy, and insulin sensitivity. , 2005, The Journal of clinical endocrinology and metabolism.

[50]  M. Amini,et al.  Comparison of the Effect of Pentoxifylline and Captopril on Proteinuria in Patients with Type 2 Diabetes mellitus , 2005, Nephron Clinical Practice.

[51]  A. Cox,et al.  Interleukin-1 receptor antagonist allele (ILIRN*2) associated with nephropathy in diabetes mellitus , 1996, Human Genetics.

[52]  J. Egido,et al.  NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[53]  H. Grønbaek,et al.  The involvement of growth hormone (GH), insulin-like growth factors (IGFs) and vascular endothelial growth factor (VEGF) in diabetic kidney disease. , 2004, Current pharmaceutical design.

[54]  Young Seol Kim,et al.  Polymorphisms in Interleukin-1β and Interleukin-1 Receptor Antagonist Genes Are Associated with Kidney Failure in Korean Patients with Type 2 Diabetes mellitus , 2004, American Journal of Nephrology.

[55]  I. Macdougall,et al.  Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. , 2004, Journal of the American Society of Nephrology : JASN.

[56]  D. Yach,et al.  The global burden of chronic diseases: overcoming impediments to prevention and control. , 2004, JAMA.

[57]  Yung-Ming Chen,et al.  Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[58]  C. Langefeld,et al.  Heritability of GFR and albuminuria in Caucasians with type 2 diabetes mellitus. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[59]  F. Gesek,et al.  Pentoxifylline Ameliorates Renal Tumor Necrosis Factor Expression, Sodium Retention, and Renal Hypertrophy in Diabetic Rats , 2004, American Journal of Nephrology.

[60]  Lin Xu,et al.  Inhibition of Tumor Necrosis Factor-α-Converting Enzyme by a Selective Antagonist Protects Brain from Focal Ischemic Injury in Rats , 2004 .

[61]  M. Crook Type 2 diabetes mellitus: a disease of the innate immune system? An update , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[62]  J. Pickup Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. , 2004, Diabetes care.

[63]  K. Yudoh,et al.  Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[64]  R. Larkins,et al.  Increased hyaluronan production in the glomeruli from diabetic rats: a link between glucose-induced prostaglandin production and reduced sulphated proteoglycan , 1995, Diabetologia.

[65]  A. Aljada,et al.  Inflammation: the link between insulin resistance, obesity and diabetes. , 2004, Trends in immunology.

[66]  R. Atkins,et al.  Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. , 2004, Kidney international.

[67]  G. Feuerstein,et al.  Inhibition of tumor necrosis factor-alpha-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats. , 2004, Molecular pharmacology.

[68]  R. Hohlfeld,et al.  Diagnostic criteria for polymyositis and dermatomyositis , 2003, The Lancet.

[69]  C. Bogardus,et al.  Variants in the interleukin 6 receptor gene are associated with obesity in Pima Indians. , 2003, Molecular genetics and metabolism.

[70]  M. Netea,et al.  Selective regulation of intercellular adhesion molecule‐1 expression by interleukin‐18 and interleukin‐12 on human monocytes , 2003, Immunology.

[71]  H. Siragy,et al.  Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. , 2003, Kidney international.

[72]  H. Makino,et al.  Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. , 2003, Diabetes.

[73]  R. Lisak,et al.  Role of Neuropoietic Cytokines in Development and Progression of Diabetic Polyneuropathy: From Glucose Metabolism to Neurodegeneration , 2003, Experimental diabesity research.

[74]  D. Yach,et al.  Globalisation and the prevention and control of non-communicable disease: the neglected chronic diseases of adults , 2003, The Lancet.

[75]  M. Bennett,et al.  Tumor Necrosis Factor-&agr; Promotes Macrophage-Induced Vascular Smooth Muscle Cell Apoptosis by Direct and Autocrine Mechanisms , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[76]  O. Hamdy,et al.  Adipokines, inflammation, and the endothelium in diabetes , 2003, Current diabetes reports.

[77]  J. Navarro,et al.  Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[78]  J. Navarro,et al.  Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[79]  J. Cardier,et al.  Differential effect of IL-18 on endothelial cell apoptosis mediated by TNF-α and Fas (CD95) , 2003 .

[80]  Masafumi Koga,et al.  Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. , 2003, Metabolism: clinical and experimental.

[81]  Z. Bloomgarden,et al.  Inflammation and insulin resistance. , 2003, Diabetes care.

[82]  L. Chessa,et al.  Six novel ATM mutations in Italian patients with classical ataxia‐telangiectasia , 2003, Human mutation.

[83]  Jun Yeun Kim,et al.  Identification of novel SNPs in the interleukin 6 receptor gene (IL6R) , 2003, Human mutation.

[84]  Joachim Spranger,et al.  Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. , 2003, Diabetes.

[85]  M. Yılmaz,et al.  Combination of Pentoxifylline with Angiotensin Converting Enzyme Inhibitors Produces an Additional Reduction in Microalbuminuria in Hypertensive Type 2 Diabetic Patients , 2003, Renal failure.

[86]  J. Vilček CHAPTER 1 – The cytokines: an overview , 2003 .

[87]  R. Zatz,et al.  Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. , 2003, Kidney international.

[88]  F. Gesek,et al.  Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. , 2003, American journal of physiology. Renal physiology.

[89]  T. Yoshikawa,et al.  Interleukin‐6 polymorphism (–634C/G) in the promotor region and the progression of diabetic nephropathy in Type 2 diabetes , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[90]  C. Edelstein,et al.  Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. , 2002, The Journal of clinical investigation.

[91]  Connie J. Wang,et al.  Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. , 2002, Kidney international.

[92]  K. Resch,et al.  IFNγ induces functional chemokine receptor expression in human mesangial cells , 2002 .

[93]  K. Resch,et al.  IFNgamma induces functional chemokine receptor expression in human mesangial cells. , 2002, Clinical and experimental immunology.

[94]  T. Hostetter Prevention of end-stage renal disease due to type 2 diabetes. , 2001, The New England journal of medicine.

[95]  S. Coppack Pro-inflammatory cytokines and adipose tissue , 2001, Proceedings of the Nutrition Society.

[96]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[97]  M. Lucia,et al.  Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. , 2001, The Journal of clinical investigation.

[98]  A. Phillips,et al.  Regulation of renal proximal tubular epithelial cell hyaluronan generation: implications for diabetic nephropathy. , 2001, Kidney international.

[99]  R. Blantz,et al.  Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. , 2001, The Journal of clinical investigation.

[100]  H. Zinger,et al.  Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFα monoclonal antibody and by pentoxiphylline , 2001, Lupus.

[101]  H. Makino,et al.  Role of macrophages in the pathogenesis of diabetic nephropathy. , 2001, Contributions to nephrology.

[102]  C. Park,et al.  High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-ϰB-dependent , 2000, Diabetologia.

[103]  D. Heudes,et al.  Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. , 2000, Diabetes.

[104]  G. Pacini,et al.  Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. , 2000, Diabetes.

[105]  F. Locatelli,et al.  End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[106]  G. Fantuzzi,et al.  IL-12–induced IFN-γ is dependent on caspase-1 processing of the IL-18 precursor , 1999 .

[107]  M. Puliti,et al.  Role of Tumor Necrosis Factor Alpha, Interleukin-1β, and Interleukin-6 in a Mouse Model of Group B Streptococcal Arthritis , 1999, Infection and Immunity.

[108]  F. Pociot,et al.  Cytokine gene polymorphism in human disease: on-line databases , 1999, Genes and Immunity.

[109]  H. Makino,et al.  Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-α and inducible nitric oxide synthase in diabetic rat glomeruli , 1999, Diabetologia.

[110]  Gerardo Heiss,et al.  Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study , 1999, The Lancet.

[111]  S. Rich,et al.  Is diabetic nephropathy inherited? Studies of glomerular structure in type 1 diabetic sibling pairs. , 1999, Diabetes.

[112]  M. Macía,et al.  Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[113]  G. Fantuzzi,et al.  IL-12-induced IFN-gamma is dependent on caspase-1 processing of the IL-18 precursor. , 1999, The Journal of clinical investigation.

[114]  D. Middleton,et al.  An interluekin 1B allele, which correlates with a high secretor phenotype, is associated with diabetic nephropathy. , 1998, Cytokine.

[115]  D. Breuillé,et al.  Cytokine modulation by PX differently affects specific acute phase proteins during sepsis in rats. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[116]  M. A. Crook,et al.  Is Type II diabetes mellitus a disease of the innate immune system? , 1998, Diabetologia.

[117]  A. Ridley,et al.  Regulation of TNF‐α‐induced reorganization of the actin cytoskeleton and cell‐cell junctions by Rho, Rac, and Cdc42 in human endothelial cells , 1998, Journal of cellular physiology.

[118]  V. Savin,et al.  TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. , 1998, Journal of the American Society of Nephrology : JASN.

[119]  Ihm Cg Monocyte chemotactic peptide-1 in diabetic nephropathy. , 1997 .

[120]  M. Elder The Role of Cytokines , 1997 .

[121]  C. Ihm Monocyte chemotactic peptide-1 in diabetic nephropathy. , 1997, Kidney international. Supplement.

[122]  H. Okamura,et al.  Cloning of a new cytokine that induces IFN-γ production by T cells , 1995, Nature.

[123]  M. Endoh,et al.  In Situ Hybridization of Interleukin 6 in Diabetic Nephropathy , 1995, Diabetes.

[124]  M. Rodríguez-Moran,et al.  Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. , 1995, Clinical nephrology.

[125]  A. At Presentación del Instituto «Reina Sofía» de Investigación Nefrológica , 1995 .

[126]  A. Ortiz,et al.  Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis. , 1995, Advances in nephrology from the Necker Hospital.

[127]  H. Brady Leukocyte adhesion molecules and kidney diseases. , 1994, Kidney international.

[128]  A. Thomson The cytokine handbook , 1994 .

[129]  Y. Tomino,et al.  Detection of serum IL-6 in patients with diabetic nephropathy. , 1994, Nephron.

[130]  Y. Tomino,et al.  mRNA Expression of Growth Factors in Glomeruli From Diabetic Rats , 1993, Diabetes.

[131]  E. Wardle Cytokines: an overview. , 1993, The European journal of medicine.

[132]  C. Ruef,et al.  Interleukin-6: an autocrine regulator of mesangial cell growth. , 1992, Kidney international.

[133]  M. Kondo,et al.  Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. , 1991, Kidney international.

[134]  J. Norton,et al.  Pentoxifylline suppression of tumor necrosis factor gene transcription. , 1991, Surgery.

[135]  L. Glimcher,et al.  Stimulated kidney tubular epithelial cells express membrane associated and secreted TNF alpha. , 1991, Kidney international.

[136]  J. Lacy,et al.  Interleukin 6 is an autocrine growth factor for mesangial cells. , 1990, Kidney international.

[137]  Jiahuai Han,et al.  Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway , 1990, The Journal of experimental medicine.

[138]  H. Mühl,et al.  Interleukin 1 and tumor necrosis factor potentiate angiotensin II- and calcium ionophore-stimulated prostaglandin E2 synthesis in rat renal mesangial cells. , 1990, Biochemical and biophysical research communications.

[139]  D. Kohan,et al.  Regulation of renal transport processes and hemodynamics by macrophages and lymphocytes. , 1990, The American journal of physiology.

[140]  G. Habermehl,et al.  Interleukin 1-α and tumor necrosis factor-α induce oxygen radical production in mesangial cells , 1990 .

[141]  G. Habermehl,et al.  Interleukin 1-alpha and tumor necrosis factor-alpha induce oxygen radical production in mesangial cells. , 1990, Kidney international.

[142]  S. Akira,et al.  Biological and clinical aspects of interleukin 6. , 1990, Immunology today.

[143]  F. Balkwill,et al.  The cytokine network. , 1989, Immunology today.

[144]  E. Seaquist,et al.  Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. , 1989, The New England journal of medicine.

[145]  J. Pfeilschifter,et al.  Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat renal mesangial cells. , 1989, Biochemical and biophysical research communications.

[146]  N. Perico,et al.  Tumor necrosis factor induces glomerular damage in the rabbit. , 1989, The American journal of pathology.

[147]  S. Matalon,et al.  Tumor necrosis factor and interleukin ICU increase vascular endothelial permeability , 1989 .

[148]  R. Ardaillou,et al.  Tumor necrosis factor stimulates prostaglandin production and cyclic AMP levels in rat cultured mesangial cells , 1988, FEBS letters.

[149]  L. Gooding,et al.  Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. , 1988, Journal of immunology.